- Home
- NSYS vs CYTH Comparison
NSYS vs CYTH Comparison
Compare NSYS & CYTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSYS
- CYTH
- Stock Information
- Founded
- NSYS 1981
- CYTH 1990
- Country
- NSYS United States
- CYTH United States
- Employees
- NSYS N/A
- CYTH N/A
- Industry
- NSYS Industrial Machinery/Components
- CYTH Biotechnology: Pharmaceutical Preparations
- Sector
- NSYS Technology
- CYTH Health Care
- Exchange
- NSYS Nasdaq
- CYTH Nasdaq
- Market Cap
- NSYS 34.6M
- CYTH 22.0M
- IPO Year
- NSYS N/A
- CYTH N/A
- Fundamental
- Price
- NSYS $12.25
- CYTH $0.81
- Analyst Decision
- NSYS
- CYTH Buy
- Analyst Count
- NSYS 0
- CYTH 3
- Target Price
- NSYS N/A
- CYTH $0.95
- AVG Volume (30 Days)
- NSYS 6.0K
- CYTH 32.1K
- Earning Date
- NSYS 11-06-2024
- CYTH 11-12-2024
- Dividend Yield
- NSYS N/A
- CYTH N/A
- EPS Growth
- NSYS 159.52
- CYTH N/A
- EPS
- NSYS 2.23
- CYTH N/A
- Revenue
- NSYS $137,529,000.00
- CYTH $1,132,430.00
- Revenue This Year
- NSYS N/A
- CYTH N/A
- Revenue Next Year
- NSYS N/A
- CYTH $24.49
- P/E Ratio
- NSYS $5.51
- CYTH N/A
- Revenue Growth
- NSYS N/A
- CYTH 24.65
- 52 Week Low
- NSYS $7.45
- CYTH $0.59
- 52 Week High
- NSYS $19.15
- CYTH $2.12
- Technical
- Relative Strength Index (RSI)
- NSYS 50.62
- CYTH 57.39
- Support Level
- NSYS $12.28
- CYTH $0.75
- Resistance Level
- NSYS $12.99
- CYTH $0.80
- Average True Range (ATR)
- NSYS 0.59
- CYTH 0.06
- MACD
- NSYS 0.01
- CYTH 0.01
- Stochastic Oscillator
- NSYS 14.81
- CYTH 100.00
About NSYS Nortech Systems Incorporated
Nortech Systems Inc is a United States-based electronic manufacturing services company. It offers value-added engineering, technical and manufacturing services and support including project management, design, testing, prototyping, manufacturing, supply chain management, and post-market services. The company's manufacturing and engineering services include complete medical devices, printed circuit board assemblies, wire and cable assemblies, and complex higher-level electro-mechanical assemblies. It operates in the Medical, Aerospace, Defense and Industrial markets with key revenue coming from Medical device and product manufacturing and related engineering services.
About CYTH Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.